Market Place
Sourcing Support
Apnimed Strengthens Team With Two Biopharmaceutical Veterans
23 Oct 2024 //
PR NEWSWIRE
Apnimed Reveals Hidden Impact Of Obstructive Sleep Apnea
09 Oct 2024 //
PR NEWSWIRE
Apnimed To Participate In Needham Biotech Forum
26 Sep 2024 //
PR NEWSWIRE
Apnimed Completes Enrollment In AD109 Phase 3 Study
19 Sep 2024 //
PR NEWSWIRE
Apnimed Osa Obesity Prevalence: Sleep 2024 Presentations Slate Robust
23 May 2024 //
GLOBENEWSWIRE
Apnimed Completes Phase 3 OSA Treatment Study Enrollment
09 May 2024 //
GLOBENEWSWIRE
Apnimed Named 2024 Best Places to Work Company by the Boston Business Journal
07 May 2024 //
GLOBENEWSWIRE
Apnimed to Participate in the 23rd Annual Needham Virtual Healthcare Conference
03 Apr 2024 //
GLOBENEWSWIRE
Apnimed to Participate in Upcoming Leerink Partners Global Biopharma Conference
06 Mar 2024 //
GLOBENEWSWIRE
Apnimed to Participate in the Evercore ISI 2024 Emerging Biotech Conference
22 Feb 2024 //
GLOBENEWSWIRE
Apnimed, a late-stage sleep apnea biotech, eyes IPO in the second half
15 Feb 2024 //
ENDPTS
Apnimed Announces New Leadership Appointments
22 Jan 2024 //
GLOBENEWSWIRE
Apnimed hires Pfizer, Biohaven veteran as chief commercial officer
22 Jan 2024 //
ENDPTS
Apnimed Announces First Patient Dosed in SynAIRgy
21 Dec 2023 //
GLOBENEWSWIRE
Apnimed to Participate in Upcoming November Investor Conferences
06 Nov 2023 //
GLOBENEWSWIRE
Apnimed Announces Launch of Joint Venture with Shionogi
31 Oct 2023 //
GLOBENEWSWIRE
Apnimed to Present Review of Data on Investigational Pharmacologic Treatment
18 Oct 2023 //
GLOBENEWSWIRE
Apnimed to Participate in Upcoming October Investor Conferences
11 Oct 2023 //
GLOBENEWSWIRE
American Journal of Respiratory Medicine Publishes Results of Apnimed
10 Oct 2023 //
GLOBENEWSWIRE
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
02 Oct 2023 //
GLOBENEWSWIRE
Two biotechs go public while Apnimed bides its time
02 Oct 2023 //
FIERCE BIOTECH
Apnimed Announces First Patient Dosed in LunAIRo
21 Sep 2023 //
GLOBENEWSWIRE
Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs
18 Sep 2023 //
GLOBENEWSWIRE
Apnimed to Present New Data on Investigational Oral Therapies
06 Sep 2023 //
GLOBENEWSWIRE
APNIMED to Participate in Upcoming Investor Conferences in September
30 Aug 2023 //
GLOBENEWSWIRE
APNIMED to Participate in 43rd Annual Canaccord Genuity Global Growth Conference
01 Aug 2023 //
GLOBENEWSWIRE
Apnimed to Participate in the William Blair Virtual Conference
12 Jul 2023 //
GLOBENEWSWIRE
Apnimed to Participate in the 2023 BIO International Convention
23 May 2023 //
GLOBENEWSWIRE
Apnimed nails study of sleep apnea med, tees up phase 3 test
22 May 2023 //
FIERCE BIOTECH
Apnimed Presented Positive Phase 2b Results on AD109
21 May 2023 //
GLOBENEWSWIRE
Apnimed to Present Positive Ph 2b Results on AD109, Investig Oral Treatment
15 May 2023 //
BUSINESSWIRE
Apnimed to Present at the 22nd Annual Needham Virtual Healthcare Conference
10 Apr 2023 //
BUSINESSWIRE
Apnimed to Participate in the SVB Securities Global Biopharma Conference
25 Jan 2023 //
BUSINESSWIRE
Apnimed Completes Oversubscribed $79.75 Million Series C Extension Financing
03 Jan 2023 //
BUSINESSWIRE
Apnimed to Present at the Stifel Healthcare Conference
08 Nov 2022 //
BUSINESSWIRE
Apnimed touts PhIIb data for lead sleep apnea program
18 Oct 2022 //
ENDPTS
Apnimed Announces Positive Topline Results for MARIPOSA Trial of AD109
17 Oct 2022 //
PRESS RELEASE
Apnimed to Participate in the Annual Needham Biotech Company Virtual 1x1 Forum
12 Oct 2022 //
BUSINESSWIRE
Apnimed Appoints John Cronin, Senior VP, Clinical Development
05 Oct 2022 //
BUSINESSWIRE
Apnimed to Participate in the 42nd Annual Canaccord Genuity Conference
04 Aug 2022 //
BUSINESSWIRE
Apnimed Granted FDA FTD for AD109 in Obstructive Sleep Apnea
28 Jun 2022 //
BUSINESSWIRE
Apnimed Adds Ruoxi Hu, Ph.D., to Its Board of Directors
16 Jun 2022 //
BUSINESSWIRE
Apnimed to Present at the Jefferies Healthcare Conference
06 Jun 2022 //
BUSINESSWIRE
New Data Show Meaningful Improvements for AD504 in Obstructive Sleep Apnea
02 Jun 2022 //
BUSINESSWIRE
Apnimed secures $62.5M to push sleep disorder drug development
04 May 2022 //
FIERCEBIOTECH
Apnimed to Participate in the 21st Annual Needham Virtual Healthcare Conference
05 Apr 2022 //
BUSINESSWIRE
Apnimed to Present at the 32nd Annual Oppenheimer Healthcare Conference
10 Mar 2022 //
BUSINESSWIRE
Apnimed Study APC-004 Phase 2 Data to be Presented at World Sleep 2022
09 Mar 2022 //
BUSINESSWIRE
Apnimed to Participate in the SVB Leerink Global Healthcare Conference
07 Feb 2022 //
BUSINESSWIRE
Apnimed Begins Dosing in Phase 2 MARIPOSA Confirmatory Trial of AD109, for OSA
16 Dec 2021 //
BUSINESSWIRE
Apnimed sees positives in new sleep apnea drug data
14 Oct 2021 //
FIERCEBIOTECH
Apnimed Announces Positive Ph2 Data (Study APC-004) Demonstrating Improvement
13 Oct 2021 //
BUSINESSWIRE
Apnimed Announces Positive Phase 2 (Study APC-003) Data
13 Oct 2021 //
BUSINESSWIRE
Apnimed Appoints Rob Rode Chief Commercial Officer
27 Sep 2021 //
BUSINESSWIRE
Apnimed to Present at the Canaccord Genuity 41st Annual Growth Conference
06 Aug 2021 //
BUSINESSWIRE
Apnimed to Present at the Canaccord Genuity 41st Annual Growth Conference
06 Aug 2021 //
BUSINESSWIRE
Apnimed to Present at the Ladenburg Thalmann Virtual Healthcare Conference
06 Jul 2021 //
BUSINESSWIRE
New Data Presented at American Thoracic Society Meeting Reinforces
17 May 2021 //
BUSINESSWIRE
Apnimed raises funding to advance sleep apnea therapeutic
26 Mar 2021 //
PHARMACEUTICAL-TECHNOLOGY
Apnimed Closes Series B Financing to Advance Once-Daily Oral for (OSA)
25 Mar 2021 //
BUSINESSWIRE
